Early-Stage trial for Friedreich's ataxia drug in kids halted
Disease control
Terminated
This early-stage study aimed to check the safety of a drug called nomlabofusp in 18 children and teenagers (ages 2 to 17) with Friedreich's ataxia, a rare genetic disease that affects movement and heart function. The drug was given as a shot under the skin. The study was stopped …
Phase: PHASE1 • Sponsor: Larimar Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC